期刊文献+

粘质沙雷菌对碳青霉烯类抗菌药物耐药机制研究进展 被引量:3

Advances in study on resistance mechanism of Serratia marcescens to carbapenems
原文传递
导出
摘要 近年来耐碳青霉烯类粘质沙雷菌的耐药率和临床分离率在逐步上升,这给医院感染防控和临床抗感染治疗工作带来了极大的挑战。粘质沙雷菌可通过携带碳青霉烯酶基因,外膜孔道蛋白的改变或缺失,主动外排机制,抗菌药物作用靶点的改变,整合子的作用等产生耐药性,本文结合国内外文献对其碳青霉烯类药物耐药机制做一综述,为临床抗细菌治疗及新型药物研发提供理论依据。 In recent years,the resistance rate and clinical isolation rate of carbapenem-resistant Serratia marcescens have been gradually increasing,which has brought great challenges to the control and clinical treatment of nosocomial infection.S.marcescens can produce drug resistance by carrying the carbapenemase genes,alteration or deletion of outer membrane pore protein,active efflux mechanism,change of target of antibacterial drug and action of integron.The mechanisms of resistance to carbapenems are reviewed based on the literatures abroad and at home,which may provide theoretical basis for clinical antibacterial treatment and development of novel drugs.
作者 袁园 王中新 朱亦林 陈继中 YUAN Yuan;WANG Zhong-xin;ZHU Yi-lin;CHEN Ji-zhong(Tong ling People's Hospital,Tongling Anhui 244000,China;不详)
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2019年第21期3355-3360,共6页 Chinese Journal of Nosocomiology
基金 安徽省高校省级自然科学研究基金资助项目(KJ2010A174)
关键词 耐碳青霉烯粘质沙雷菌 外膜孔道蛋白 外排泵 青霉素结合蛋白 整合子 碳青霉烯酶 Carbapenem-resistant Serratia marcescens Outer membrane pore protein Efflux pump Penicillin-binding protein Integron Carbapenemase
  • 相关文献

参考文献7

二级参考文献50

  • 1Voelz A, MUller A, Gillen J, et al. Outbreaks of Serratia marcescens in neonatal and pediatric intensive care units: clinical aspects, risk factors and management. Int J Hyg Environ Health, 2010, 213:79-87.
  • 2Lima KV, Carvalho RG, Carneiro IC, et al. Outbreak of neonatal infection by an endemic clone of Serratia mareescens. Rev Soc Bras Med Trop, 2011,44:106-109.
  • 3Bush K, Pannell M, Lock JL, et al. Detection systems for carbapenemase gene identification should include the SME serine carbapenemase. Int J Antimicreb Agents, 2013, 41:1-4.
  • 4Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases[J]. Clin Mierobiol, 2007,20 (3): 440- 458.
  • 5Boyd DA, Delport J, Hoang harbouring SME-type class L,et al. Serratia marcescens A carbapenemases in Cana da and the presence of blaSME on a novel genomic is- land, SmarGIl-1 [J]. Antimicrob Chemother, 2014, 69 (7) :1825-1829.
  • 6Queenan AM, Shang W, Schreckenberger P, et al. SME 3, a novel member of the Serratia mareescens SME fam- ily of carbapenem hydrolyzing beta-lactamases[J]. An timicrob Agents Chemother. , Z006,50 (10) .. 3485 -3487.
  • 7Carrer A, Poirel L, Pitout JD, et al. Occurrence of an SME-2-producing Serratia marcescens isolate in Canada [J]. Antimicrob Agents,2008,31(2) ..181-182.
  • 8Peleg AY, Franklin C, Bell JM, et al. Dissemination of the metallo-beta-lactamase gene blaIMP 4 among gram- negative pathogens in a clinical setting in Australia[J]. Clin Infect Dis,2005,41(11) ..1549-1556.
  • 9Clinical and Laboratory Standads Institute.Performance standardsfor antimicrobial susceptibility testing[S].Sixteenth Informational Supplement,2014,M100-S24.
  • 10Tygacil(tigecycline)iv injection label-US FDA[S/OL].2013,Reference ID:3379756.[2015-03-31].http://www.accessdata.fda.gov/ drugsatfda-docs/label/2013/021821 s026s031 lbl.pdf.

共引文献62

同被引文献34

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部